Search Results - "Ricigliano, Mark"

  • Showing 1 - 11 results of 11
Refine Results
  1. 1

    ADR-201: A novel cytotoxic drug-conjugate for pancreatic cancer by Ricigliano, Mark, Cooper, Brandon, Bartlett, Andrew, Yu, Kenneth H.

    Published in Journal of clinical oncology (20-05-2017)
    “…Abstract only e14018 Background:Standard of care treatment for pancreatic adenocarcinoma (PDAC) consists of FOLFIRINOX or gemcitabine with nab-paclitaxel used…”
    Get full text
    Journal Article
  2. 2

    Use of phenotypic profiling to determine sensitivity of gemcitabine with nab-paclitaxel for front-line treatment of pancreatic cancer by Ricigliano, Mark, Cooper, Brandon, Bartlett, Andrew, Yu, Kenneth H.

    Published in Journal of clinical oncology (20-05-2017)
    “…Abstract only e15749 Background: Standard of care treatment for pancreatic adenocarcinoma (PDAC) consists of FOLFIRINOX (FFX) or gemcitabine with…”
    Get full text
    Journal Article
  3. 3
  4. 4
  5. 5

    Evaluation of a cell viability assay based on cultures of CTICs to identify treatment options in third-line pancreatic cancer by Ricigliano, Mark, Isacoff, William H., Ocean, Allyson J., Cooper, Brandon, Welkie, Mary, Bartlett, Andrew, Yu, Kenneth H.

    Published in Journal of clinical oncology (01-02-2017)
    “…Abstract only 338 Background: Standard of care treatment for pancreatic adenocarcinoma (PDAC) includes FOLFIRINOX or gemcitabine with nab-paclitaxel used in…”
    Get full text
    Journal Article
  6. 6
  7. 7

    Circulating Tumor and Invasive Cell Gene Expression Profile Predicts Treatment Response and Survival in Pancreatic Adenocarcinoma by Yu, Kenneth H, Ricigliano, Mark, McCarthy, Brian, Chou, Joanne F, Capanu, Marinela, Cooper, Brandon, Bartlett, Andrew, Covington, Christina, Lowery, Maeve A, O'Reilly, Eileen M

    Published in Cancers (24-11-2018)
    “…Previous studies have shown that pharmacogenomic modeling of circulating tumor and invasive cells (CTICs) can predict response of pancreatic ductal…”
    Get full text
    Journal Article
  8. 8
  9. 9

    Feasibility to obtain a chemogram in circulating tumorigenic cells to guide further treatments in refractory solid tumors by Cubillo, Antonio, Calles, Antonio, López-Casas, Pedro P., Ricigliano, Mark, Calvo, Emiliano, Duran, Ignacio, López-Ríos, Fernando, Rodriguez, Margarita, Hidalgo, Manuel

    Published in Journal of clinical oncology (20-05-2012)
    “…Abstract only 3066 Background: Circulating tumorigenic cells (CTCs) may be responsible for tumor progression, represent a new source of information of tumor…”
    Get full text
    Journal Article
  10. 10

    Use of pharmacogenomic modeling in pancreatic cancer for prediction of chemotherapy response and resistance by Yu, Kenneth H., Sangar, Vineet, Ricigliano, Mark, Hidalgo, Manuel, Abou-Alfa, Ghassan K., Lowery, Maeve Aine, Saltz, Leonard, Crotty, Joseph F., Gary, Kristen, Yin, Jing, Choi, Eun Yong, O'Reilly, Eileen Mary

    Published in Journal of clinical oncology (20-05-2013)
    “…Abstract only 4017 Background: Pancreatic adenocarcinoma (PDAC) is uniformly lethal and is the 4th leading cause of cancer mortality. Despite this, modern…”
    Get full text
    Journal Article
  11. 11

    Use of pharmacogenomic modeling in pancreatic cancer for prediction of chemotherapy response and resistance by Sangar, Vineet, Ricigliano, Mark, O'Reilly, Eileen Mary, Abou-Alfa, Ghassan K., Lowery, Maeve Aine, Saltz, Leonard, Crotty, Joseph F, Gary, Kristen, Choi, Eun Yong, Yin, Jing, Hidalgo, Manuel, Yu, Kenneth H.

    Published in Journal of clinical oncology (01-02-2013)
    “…Abstract only 142 Background: Pancreatic adenocarcinoma (PDAC) is uniformly lethal; despite this, modern cytotoxics (C) can induce tumor responses and extend…”
    Get full text
    Journal Article